{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5f2442bc6de29f32c4d05451/62ea8c353aedc70012e3a8db?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"rAAVs, host-cell contamination and ddPCR","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/5f2442bc6de29f32c4d05451/1659538772581-065ecb0655c77314362c55f6443d0076.jpeg?height=200","description":"<p>In this episode of Talking Techniques, supported by Bio-Rad, we discuss a key component of many gene therapies: recombinant adeno-associated viruses (rAAVs) and their production. These viruses act as efficient, accurate delivery vesicles for the gene therapy’s plasmid.</p><p><br></p><p>Speaking to Associate Director of Biopharma Product Marketing at&nbsp;Bio-Rad&nbsp;Laboratories, Mark White, we take a look at the different expression systems used for their production and compare their advantages, before looking at some of the challenges involved in the production rAAVs, such as host-cell contamination.</p><p><br></p><p>Discover the tools that can help minimize host-cell contamination and differentiate between nuclease resistant and nuclease reactive contaminant DNA and find out about some of the most exciting developments in rAAV technologies.&nbsp;</p><p><br></p><h2>Contents:</h2><ul><li>The role of rAAVs in gene therapies: 00:40-02:15</li><li>The production of rAAVs and gene therapies: 02:15-03:30</li><li>Why are HEK cells so popular for cell therapy production? 03:30-05:45</li><li>HEK vs SF9 Insect cell expression systems: 05:45-06:45</li><li>Challenges in cell therapy expression systems: 06:45-08:05</li><li>Host DNA contamination: 08:05-10:30</li><li>The risks of host DNA contamination: 10:30-12:45</li><li>Key techniques to minimize host DNA contamination: 12:45-14:40</li><li>The advantages of ddPCR in gene therapy production: 14:40-17:50</li><li>Distinguishing between nuclease resistant and nuclease reactive host cell DNA: 17:50-19:10</li><li>The most exciting developments in rAAV technology: 19:10-20:20</li><li>What is one thing you would ask for to improve rAAV and gene therapy development 20:20-26:38</li></ul>","author_name":"BioTechniques"}